Cogent Biosciences Inc

NASDAQ COGT

Data sourced from

and

Download Data

Cogent Biosciences Inc Working Capital To Sales Ratio for the year ending December 31, 2023

Cogent Biosciences Inc Working Capital To Sales Ratio is NA for the year ending December 31, 2023. The working capital to sales ratio measures the proportion of working capital to revenue. It is calculated by dividing the difference between current assets and current liabilities by revenue. This ratio provides insights into the efficiency of working capital utilization relative to revenue generation. A higher ratio suggests better utilization of working capital to generate sales revenue.

Cogent Biosciences Inc Working Capital To Sales Ratio for the year ending December 31, 2020 was 29.45, a 2,323.45% change year over year.
Cogent Biosciences Inc Working Capital To Sales Ratio for the year ending December 31, 2019 was 1.22, a -78.90% change year over year.

NASDAQ: COGT

Cogent Biosciences Inc

CEO	Mr. Andrew R. Robbins M.B.A.
IPO Date	March 29, 2018
Location	United States
Headquarters	200 Cambridge Park Drive, Cambridge, MA, United States, 02140
Employees	164
Sector	Healthcare
Industry	Biotechnology

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Key trends